5:47 PM
 | 
Feb 15, 2017
 |  BC Extra  |  Politics & Policy

UC undeterred by CRISPR patent ruling

A University of California group is optimistic that its CRISPR IP rights will cover use of the technology in all cell types, despite a U.S. patent board's ruling Wednesday that an opposing group's IP is patentable separately. The ruling, issued by the U.S. Patent Trial and Appeals board, terminated an interference proceeding which could have blocked a patent held by The Broad Institute of MIT and Harvard and co-inventor Feng Zhang.

The ruling may require gene editing companies to license CRISPR IP from both parties, according to a lawyer representing UC. Lynn Pasahow, an attorney with Fenwick & West who is representing the school, said on a conference call Wednesday that the university...

Read the full 554 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >